| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2008, p. 1613-1617, Vol. 52, No. 5
0066-4804/08/$08.00+0 doi:10.1128/AAC.00978-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Wejdene Mansour,1,2,
Olfa Bouallegue,2 and
Patrice Nordmann1*
Service de Bactériologie-Virologie, INSERM U914, Emerging Resistance to Antibiotics, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine et Université Paris Paris-Sud, K.-Bicêtre 94275, France,1 Unité de Recherche Infections à Bactéries Multirésistantes aux Antibiotiques (UR/29/04), Laboratoire de Microbiologie, CHU Sahloul, 4054 Sousse, Tunisia2
Received 12 July 2007/ Returned for modification 11 November 2007/ Accepted 19 February 2008
The basis of the β-lactam resistance of 39 multidrug-resistant Acinetobacter baumannii isolates recovered from hospitalized patients was studied. These isolates were collected from 2001 to 2005 at the Sahloul Hospital in Sousse, Tunisia. They belonged to two distinct clones. One clone that grouped 19 isolates produced a carbapenem-hydrolyzing oxacillinase, OXA-97, that differed from OXA-58 by a single amino acid substitution and conferred the same β-lactam resistance profile as OXA-58. The blaOXA-97 gene was located on plasmids that varied in size in 18 isolates and was chromosomally located in a single isolate. Cloning and sequencing identified genetic structures surrounding the blaOXA-97 gene similar to those reported to be adjacent to the blaOXA-58 gene. In addition, the novel ISAba8 element (which is of the IS21 family) was identified. This is the first report of the nosocomial spread of carbapenemase producers in A. baumannii isolates in Africa.
Published ahead of print on 25 February 2008.
L.P. and W.M. contributed equally to this work.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |